
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC is positioned favorably in the biotechnology sector, supported by its ImmTAX platform that is generating a deep pipeline across multiple therapeutic areas including oncology and infectious diseases. The company's lead product, KIMMTRAK, has shown significant survival benefits in metastatic uveal melanoma, alongside strong early sales and market penetration, which contribute to a positive revenue outlook. Additionally, the potential advancements in HIV treatment with drug candidates such as IMC-M113V further reinforce a bullish perspective on Immunocore's capability in developing innovative therapies.
Bears say
Immunocore Holdings PLC faces several challenges that contribute to a negative outlook on its stock. The company's bear case assumptions indicate a lack of observed clinical benefit for key programs, including IMC-F106C, leading to significantly reduced positive outcomes in critical indications such as PROC and NSCLC, thereby implying potential downside risks to its projected financial metrics. Additionally, the company's efforts in developing successful clinical candidates outside its established ImmTAC, ImmTAV, and ImmTAI platforms are complicated by treatment safety, scalability, and accessibility issues associated with complex diseases like HIV, which poses substantial obstacles to generating meaningful returns from its pipeline.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares